OLC received a Complete Response Letter from the FDA due to manufacturing deficiencies unrelated to the drug itself, ...

Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and ...

Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of ...

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

The researchers behind the new AI system explained IPF is a good candidate for this type of technology, since existing ...

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple ...

Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard ...